Health Condition 1: L509- Urticaria, unspecified
Conditions
Interventions
Intervention1: Tablet Bilastine 20 mg: 20 mg once daily for 12 Weeks
Control Intervention1: Tablet Levocetirizine 10 mg: 5 mg twice daily for 12 weeks
Sponsors
Dr Jaydev Singh
Eligibility
Inclusion criteria
Inclusion criteria: Patients of acute & chronic urticaria aged between 18-75 years. Patients who are willing to give written informed consent Patients with minimum UAS of 5 or greater than it
Exclusion criteria
Exclusion criteria: Patients with : Urticarial vasculitis Senile prutitus Drug induced urticaria Herediatary angioedema will be excluded Patient taken antihistaminic in last 4 weeks Patient taken corticosteroid in last 4 weeks Patient having known hypersensitivity to the drug Patients on immunosuppressive therapy ( cyclosporine, methotrexate, azathioprine) Pregnant and lactating females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary : To compare UAS (Urticaria Actrivity Score) between both groups at end of 12 weeks. Timepoint: AT END OF 4TH, 8TH, 12TH WEEK | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To observe % of non responders 2.To observe % of dose increased 3. To observe number of patients in whom corticosteroid was given 4. To observe any adverse drug effects, if occurred. 5.To compare the safety of Tab Bilastine 20mg Vs Tab Levocetirizine 10mg Timepoint: AT END OF 4TH, 8TH, 12TH WEEK | — |
Countries
India
Contacts
Public ContactDr Jaydev Singh
Government Medical College, Bhavnagar
Outcome results
None listed